Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in san francisco, 1986-1992

Journal of Acquired Immune Deficiency Syndromes

Volumn 7, Issue 12, 1994, Pages 1276-1281

  Watters, John K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bleach; Condoms; Drug users; Human immunodeficiency virus; Knowledge diffusion; Outreach; Prevention; Risk behavior; Seroprevalence

Indexed keywords

ARTICLE; DRUG USE; HEALTH BEHAVIOR; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROEPIDEMIOLOGY; UNITED STATES;

CONDOMS; CONTRACEPTION BEHAVIOR; CROSS-SECTIONAL STUDIES; DISINFECTION; FEMALE; HIV SEROPREVALENCE; HUMAN; LOGISTIC MODELS; MALE; NEEDLE SHARING; NEEDLES; RISK-TAKING; SAN FRANCISCO; SEX BEHAVIOR; SODIUM HYPOCHLORITE; SUBSTANCE ABUSE, INTRAVENOUS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028171541     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/00126334-199412000-00009     Document Type: Article

References (37)

1. Stoneburner RL, Des Jarlais DC, Benezra D, et al. A larger spectrum of HIV-1 related disease in intravenous drug users in New York City. Science 1988;242:916-9.
2. Wormser GP, AIDS and other manifestations of HIV infection, 2nd ed. New York: Raven Press, 1992.
3. Wiley JA, Samuel MC. The prevalence of HIV infection in the USA. AIDS 1989;3(suppl 1):71-8.
4. Prebble E, Miller T. Methadone, wine, and welfare. In: Wepner RS, ed. Street ethnography: selected studies of crime and drug abuse in natural settings. Beverly Hills. CA: Sage Publications, 1977:229-48.
5. Cushman P. Methadone maintenance: long term follow-up of detoxified patients. Ann NY Acad Sci 1978:311:165-72.
6. Cooper JR. Altman F, Brown BS. Czechozich D. Research on the treatment of narcotic addiction: state of the art. Rockville, MD: National Institute on Drug Abuse, 1983. U.S. Department of Health and Human Services publication ADM 83-1281.
7. Dole VP. Methadone treatment and the acquired immunodeficiency syndrome epidemic. JAMA 1989;262:1681-2.
8. D’Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA 1992:267: 253-8.
9. Oliveto A, Koster T, Schottenfeld R, Ziedonis D. Cocaine abuse among methadone-maintenanced patients. Am J Psychiatry 1993:150:1755.
10. Broadhead RS. Social constructions of bleach in combating AIDS among injection drug users. J Drug Issues 1991;21: 322-48.
11. Watters JK, Newmeyer JA, Feldman HW, Biernacki P. Street-based AIDS prevention for intravenous drug users in San Francisco: prospects, options, and obstacles. II:37—43; Select Issues: Acquired Immune Deficiency Syndrome (AIDS), Drug Abuse and Crime, Ethnographic Research, International Research. Community Epidemiology Work Group Proceedings, June, 1986. National Institute on Drug Abuse, Rockville, MD, 1986.
12. Resnick L, Varen K, Salahuddin SZ, Tondreau S, Markham PD. Stability and inactivation of HTLV-III/LAV under clinical and laboratory conditions. JAMA 1986;255:1887-91.
13. Froner GA, Rutherford GW, Rokeach M. Injection of sodium hypochlorite by intravenous drug users. JAMA 1987; 258:325.
14. Watters JK, Downing M, Case P, et al. AIDS prevention for intravenous drug users in the community: street-based education and risk behavior. Am J Comm Psych 1990; 18(4):587- 96.
15. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Prob 1989;36:416-30.
16. Newmeyer JA, Feldman HW, Biernacki P, Watters JK. Preventing AIDS contagion among intravenous drug users. Med Anthropol 1989; 10:167.
17. Watters JK. Historic perspective on the use of bleach in HIV/AIDS prevention. J Acquir Immune Defic Syndr 1994;7:743-6.
18. Shapshak P, McCoy CB, Rivers JE, et al. Inactivation of human immunodeficiency virus, type-1 at short time intervals using undiluted bleach [Letter]. J Acquir Immune Defic Syndr 1993;6:218-9.
19. Vlahov D, Munoz A, Celentano DD, et al. HIV seroconversion and disinfection of injection equipment among injection drug users, Baltimore, MD. Epidemiology 1991;2:444-6.
20. Vlahov D, Astemborski J, Solomon L, Nelson KE. Field effectiveness of needle disinfection among injecting drug users. J Acquir Immune Defic Syndr 1994;7:760-6.
21. Shapshak P, McCoy CB, Shah SM, et al. Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr 1994;7:754-9.
22. Gleghom AA, Doherty MC, Vlahov D, Celentano DD, Jones TS. Inadequate bleach contact times during syringe cleaning among injection drug users. J Acquir Immune Defic Syndr 1994;7:767-72.
23. Flynn N, Jain S, Keddie EM, et al. In vitro activity of readily available household materials against HIV-1: is bleach enough? J Acquir Immune Defic Syndr 1994;7:747-53.
24. Watters JK, Jones TS, Shapshak P, et al. Household bleach as disinfectant for use by injecting drug users. Lancet 1993; 147:742-3.
25. U.S. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives. Washington, D.C.: U.S. Government Printing Office, 1991. U.S. Department of Health and Human Services publication no. (PHS) 91-50212.
26. Watters JK, Estilo MJ, Clark GL, Lorvick JL. Syringe and needle-exchange as H1V/A1DS prevention for injection drug users. JAMA 1994;271:115-20.
27. CDC. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR 1989;37(S-7).
28. Lifson AR, Watters JK, Thompson S, Crane CM, Wise F. Discrepancies in tuberculin skin test result with two commercial products in a population of intravenous drug users. J Inject Dis 1993;168:1048-51.
29. SPSS Inc. SPSS reference guide. Chicago: SPSS Inc., 1990.
30. Shade SB, Estilo MJ, Watters JK. Characteristics and risk behaviors of new injectors. Presented at the Ninth International Conference on AIDS, Berlin, Germany, 1993.
31. Guydish J, Bucardo J, Young M, et al. Evaluating needle exchange: are there negative effects? AIDS 1993;7:871-6.
32. CDC. Update: reducing HIV transmission in intravenous- drug users not in drug treatment United States. MMWR 1990;39(31):529—38.
33. Watkins KE, Metzger D, Woody G, A.T. M. Determinants of condom use among intravenous drug users. AIDS 1993; 1993:719-24.
34. Lewis DK. Watters JK. Sexual risk behavior among heterosexual drug users: ethnic and gender variations. AIDS 1991; 5:77-83.
35. Catania JA, Coates TJ. Stall R, et al. Prevalence of AIDS- related risk factors and condom use in the United States. Science 1992;258:1101-6.
36. Moss AR, Vranizan K, Gorter R, et al. Seroconversion for HIV in San Francisco intravenous drug users, 1985-1990. AIDS 1994;8:223-31.
37. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic. JAMA 1994;271:121-7.